Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (23493)	4/18/2007 4:01:39 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Neither Harry nor I are making the argument that you're implying has been made. I don't disagree - I'm just trying to argue what happens if you take the recent FDA position to its logical conclusion. If you have to demonstrate "superiority" over existing approved drugs then the hurdle is extremely high. Even if the new drug is in fact somewhat better, it is extremely hard to prove it so absent huge trials. That standard would indeed mean that the first few drugs across the finish line would be the only ones approved. As a concrete example, I don't believe we will ever see another antibiotic approved for acute bacterial sinusitis unless the FDA radically revises their current approach. ABS is responsible for a big chunk of the primary care antibiotic market, and so the incentives to develop new mass-market antibiotics have been markedly reduced. Peter